HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE METASTATIC BREAST CANCER

Clinical trials for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE METASTATIC BREAST CANCER explained in plain language.

Never miss a new study

Get alerted when new HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE METASTATIC BREAST CANCER trials appear

Sign up with your email to follow new studies for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New combo therapy aims to fight breast cancer in the bones

Disease control Recruiting now

This study is testing whether adding an investigational drug called zunsemetinib to the standard chemotherapy capecitabine is safe and effective for people with a specific type of advanced breast cancer that has spread to the bones. The goal is to see if this combination can bett…

Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE METASTATIC BREAST CANCER

Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control

Last updated Apr 02, 2026 05:57 UTC

HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE METASTATIC BREAST CANCER

Get alerted when new HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE METASTATIC BREAST CANCER trials appear

New combo therapy aims to fight breast cancer in the bones